Roberts eliminates backlog of annual reports cited in FDA warning letter.
ROBERTS ANNUAL REPORT BACKLOG CLEARED FOLLOWING FDA WARNING LETTER that cites the firm for failing to make required reports for approved NDAs. Roberts Pharmaceutical said that it has eliminated the backlog of annual reports that were of concern to FDA. "Your firm has no system for maintaining required records and has failed to maintain required records or make required reports in several instances...regarding approved new drug applications," the Dec. 31 warning letter states.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth